Login / Signup

Real-World Experience in the Use of Immunosuppression for the Management of Inflammatory Eye Disease.

Matthew AzzopardiYu Jeat ChongSreekanth SreekantamRobert J BarryNatraj PoonitSaaeha RauzPhilip I Murray
Published in: Ocular immunology and inflammation (2024)
Progressive conditions, such as cicatrising conjunctivitis may require lifelong immunosuppression, but patients with NIU and Scleritis and those on CTSS, immunosuppression withdrawal should be considered if they remain in remission for 2 years. Any patient stopping a medication should be contacted immediately for counselling. These data will better inform patients, encourage adherence and aide formal guideline development.
Keyphrases